Savara Inc.

Healthcare · Biotechnology · United States

Last price 4.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.22B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.